AR059356A1 - Nuevos radioligandos - Google Patents

Nuevos radioligandos

Info

Publication number
AR059356A1
AR059356A1 ARP070100511A ARP070100511A AR059356A1 AR 059356 A1 AR059356 A1 AR 059356A1 AR P070100511 A ARP070100511 A AR P070100511A AR P070100511 A ARP070100511 A AR P070100511A AR 059356 A1 AR059356 A1 AR 059356A1
Authority
AR
Argentina
Prior art keywords
radioligands
new
compound
receptor
brain
Prior art date
Application number
ARP070100511A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR059356A1 publication Critical patent/AR059356A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente se refiere a nuevos radioligandos para el receptor 5-HT1B (receptor dopaminérgico). Estos compuestos pueden ser utilizados para monitorear la depresion en humanos mediante la medicion de la distribucion espacial de dicho compuesto en el cerebro. Reivindicacion 1: Un compuesto isotopicamente marcado de la formula 1, o una sal farmacéuticamente aceptable del mismo, donde el compuesto comprende al menos una marca isotopica seleccionada de 3H, 11C, 13N o 15O.
ARP070100511A 2006-02-14 2007-02-07 Nuevos radioligandos AR059356A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77330206P 2006-02-14 2006-02-14

Publications (1)

Publication Number Publication Date
AR059356A1 true AR059356A1 (es) 2008-03-26

Family

ID=38371808

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100511A AR059356A1 (es) 2006-02-14 2007-02-07 Nuevos radioligandos

Country Status (8)

Country Link
US (1) US20090004106A1 (es)
EP (1) EP1987017A4 (es)
JP (1) JP2009532328A (es)
CN (1) CN101384578A (es)
AR (1) AR059356A1 (es)
TW (1) TW200804363A (es)
UY (1) UY30146A1 (es)
WO (1) WO2007094718A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
LT2247558T (lt) * 2008-02-14 2022-04-11 Eli Lilly And Company Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui
EP2323697A2 (en) 2008-07-24 2011-05-25 Siemens Medical Solutions USA, Inc. Imaging agents useful for identifying ad pathology
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2751125C (en) * 2009-01-29 2017-06-20 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US8367676B2 (en) 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774
JP5847194B2 (ja) 2010-12-20 2016-01-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ ２−カルボキサミド−４−ピペラジニル−ベンゾフラン誘導体
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3506894B1 (en) 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
WO2019017995A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ526699A (en) * 2001-01-16 2005-03-24 Astrazeneca Ab 8-amino derivatives and their use in treating migraine
MXPA03006250A (es) * 2001-01-16 2003-09-22 Astrazeneca Ab Compuestos heterociclicos terapeuticos.
BR0206513A (pt) * 2001-01-16 2004-01-06 Astrazeneca Ab Composição, métodos de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de qualquer um dos compostos, composição farmacêutica, e, processo para preparar compostos
AU2002336749A1 (en) * 2001-09-21 2003-04-01 Pharmacia And Upjohn Company Tricyclic indole derivatives as 5-ht ligands
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
CA2475254A1 (en) * 2002-03-04 2003-09-18 Pharmacia & Upjohn Company Pyridinyloxy derivatives as 5-ht receptor ligands

Also Published As

Publication number Publication date
CN101384578A (zh) 2009-03-11
WO2007094718A1 (en) 2007-08-23
UY30146A1 (es) 2007-09-28
US20090004106A1 (en) 2009-01-01
JP2009532328A (ja) 2009-09-10
EP1987017A4 (en) 2010-08-25
EP1987017A1 (en) 2008-11-05
TW200804363A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
CL2011000237A1 (es) Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico.
UY30146A1 (es) Radioligandos novedosos
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
CR10674A (es) Inhibidores de la metaloproteinasa matriz
NI201400121A (es) Compuestos de indol e indazol que activan la ampk
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
HRP20090235A2 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub>
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
CL2011002287A1 (es) Compuestos derivados de 8-fenoxi-1,1-dioxido-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepina, moduladores de receptores ampa y nmda; composicion farmaceutica; procedimiento de prepapacion; y su uso para tratar enfermedades neurodegenerativas progresivas, alzheimer, parkinson, corea de huntington, entre otras; compuesto intermediario.
ECSP099490A (es) Métodos de fabricación y uso de compuestos y composiciones
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
ES2380489T8 (es) Proceso para la síntesis de compuestos orgánicos
PA8840901A1 (es) Nuevo procedimiento de resolución de enantiómeros de (3,4-dimetoxi-biciclo[4.2.0]octa-1,3,5-trien-7-il, aplicación en la sistesis de ivabradina
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
NI201300072A (es) Derivados de heteroarilo como moduladores nachr alfa 7
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
GT200600030A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
EP2174678A4 (en) ELECTRON STERILIZATION PROCESS
AR074379A1 (es) Inhibidor de triazolotiadiazola de la proteina quinasa c-met
ATE495167T1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
UY31460A1 (es) Procedimiento de preparacion de compuestos morfinicos
NI200700299A (es) Composicion de liberación modificada de al menos una forma de venlafaxina
EP2374479A4 (en) COMPOSITION WITH CONTROLLED RELEASE FOR PRODUCING UDENAFIL-CONTAINING PREPARATION WITH DELAYED RELEASE
CL2008001162A1 (es) Compuestos derivados de piperidina, antagonista del receptor de taquiquinina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal, una enfermedad del sistema nervioso central.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal